Oculis is a clinical stage biotechnology company focused on the development of novel and transformative topical treatments (eye drops) for ophthalmic diseases for both back and front of the eye. Oculis’ novel eye-drop treatments provide an unprecedented technical advance in ocular drug delivery, particularly for the back-of-the-eye diseases that are currently managed by invasive methods only such as intraocular injections or implants. Oculis’ novel eye-drop treatments are based on its proprietary solubilizing nanoparticle (SNP) technology that improves both the ability to formulate drugs as eye drops and their bio availability in the eye tissues including both the front and the back of the eye.
Oculis’ most advanced product candidate based on the solubilizing nanoparticle (SNP) technology is OC-118. OC-118 is being developed in diabetic macular edema (DME) and in front of the eye indications.
OC-118 would be the first eye drops to treat DME. Available drugs for DME are invasive, either intravitreal injections or implants and current treatments.
Get in touch
For enquiries about Oculis please contact us at: firstname.lastname@example.org.